Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer.

Front Immunol · 2023 · PMC10090448 · PMID 37063927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although the trial results indicated that maintenance nivolumab monotherapy or combination therapy was not effective for patients with ES-SCLC, patients in the combination group showed a trend toward benefit.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.